Seung H. Choi - Publications

The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine.

Journal: The Korean journal of internal medicine

Published: December 17, 2022

A conjugate of chlorin e6 and cationic amphipathic peptoid: a dual antimicrobial and anticancer photodynamic therapy agent.

Journal: Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology

Published: August 08, 2022

Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemia.

Journal: Bone marrow transplantation

Published: January 14, 2022

Genetic changes during leukemic transformation to secondary acute myeloid leukemia from myeloproliferative neoplasms.

Journal: Leukemia research

Published: August 09, 2021

RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.

Journal: Scientific reports

Published: September 27, 2019

Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse.

Journal: Blood

Published: April 27, 2018

Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype.

Journal: Oncotarget

Published: April 28, 2017

5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia.

Journal: Oncotarget

Published: July 25, 2016

Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy.

Journal: Blood

Published: April 04, 2016

Erratum to: Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.

Journal: Annals of hematology

Published: December 04, 2015

Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.

Journal: Annals of hematology

Published: June 17, 2015

Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.

Journal: Annals of hematology

Published: May 08, 2015